Teva Pharmaceuticals has announced the launch of Fluticasone Furoate Teva 27.5 micrograms/spray, nasal spray, suspension. This product is indicated in adults, adolescents, and children (six years and over) for the treatment of the symptoms of allergic rhinitis.
For any queries or further information, contact your local Teva representative. Further product information is available upon request or from the summary of product characteristics available at www.hpra.ie
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie
Adverse events should also be reported to Teva UK Limited on +44 (0) 207 540 7117 or medinfo@tevauk.com
Leave a Reply
You must be logged in to post a comment.